Synthesis of aligned porous poly(epsilon-caprolactone) (PCL)/hydroxyapatite (HA) composite microspheres
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Mi-Jin | - |
dc.contributor.author | Koh, Young-Hag | - |
dc.date.accessioned | 2021-09-06T01:41:08Z | - |
dc.date.available | 2021-09-06T01:41:08Z | - |
dc.date.created | 2021-06-18 | - |
dc.date.issued | 2013-05-01 | - |
dc.identifier.issn | 0928-4931 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/103256 | - |
dc.description.abstract | We synthesized poly(epsilon-caprolactone) (PCL)/hydroxyapatite (HA) composite microspheres with an aligned porous structure and evaluated their potential applications in bone tissue engineering. A range of HA particles (0, 5, 10 and 20 wt.% in relation to the PCL polymer) were added to a PCL solution in order to improve the biocompatibility of the porous PCL/HA composite microspheres. All the synthesized microspheres showed that the HA particles were distributed well in the PCL matrix, while preserving their aligned porous structure. The average size of the PCL/HA composite microspheres increased from 62 +/- 7 to 179 +/- 95 mu m with increasing HA content from 0 to 20 wt.%. The incorporation of the HA particles to the PCL polymer led to a considerable improvement in in vitro bioactivity, which was assessed by immersing the PCL/HA composite microspheres in simulated body fluid (SBF). A number of apatite crystals could be precipitated on the surface of the aligned porous PCL/HA composite microspheres after soaking in the SBF for 7 days. (C) 2013 Elsevier B.V. All rights reserved. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | ELSEVIER SCIENCE BV | - |
dc.subject | CONTROLLED DRUG-RELEASE | - |
dc.subject | CRYSTALLIZATION BEHAVIOR | - |
dc.subject | POLYMER MICROSPHERES | - |
dc.subject | IN-VITRO | - |
dc.subject | GELATIN | - |
dc.subject | MICROPARTICLES | - |
dc.subject | SYSTEM | - |
dc.subject | VIVO | - |
dc.title | Synthesis of aligned porous poly(epsilon-caprolactone) (PCL)/hydroxyapatite (HA) composite microspheres | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Koh, Young-Hag | - |
dc.identifier.doi | 10.1016/j.msec.2013.01.051 | - |
dc.identifier.scopusid | 2-s2.0-84875209860 | - |
dc.identifier.wosid | 000317528700055 | - |
dc.identifier.bibliographicCitation | MATERIALS SCIENCE & ENGINEERING C-MATERIALS FOR BIOLOGICAL APPLICATIONS, v.33, no.4, pp.2266 - 2272 | - |
dc.relation.isPartOf | MATERIALS SCIENCE & ENGINEERING C-MATERIALS FOR BIOLOGICAL APPLICATIONS | - |
dc.citation.title | MATERIALS SCIENCE & ENGINEERING C-MATERIALS FOR BIOLOGICAL APPLICATIONS | - |
dc.citation.volume | 33 | - |
dc.citation.number | 4 | - |
dc.citation.startPage | 2266 | - |
dc.citation.endPage | 2272 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Materials Science | - |
dc.relation.journalWebOfScienceCategory | Materials Science, Biomaterials | - |
dc.subject.keywordPlus | CONTROLLED DRUG-RELEASE | - |
dc.subject.keywordPlus | CRYSTALLIZATION BEHAVIOR | - |
dc.subject.keywordPlus | POLYMER MICROSPHERES | - |
dc.subject.keywordPlus | IN-VITRO | - |
dc.subject.keywordPlus | GELATIN | - |
dc.subject.keywordPlus | MICROPARTICLES | - |
dc.subject.keywordPlus | SYSTEM | - |
dc.subject.keywordPlus | VIVO | - |
dc.subject.keywordAuthor | Polymer | - |
dc.subject.keywordAuthor | Composite | - |
dc.subject.keywordAuthor | Hydroxyapatite | - |
dc.subject.keywordAuthor | Pore | - |
dc.subject.keywordAuthor | In vitro bioactivity | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.